Aytu BioPharma Inc. (AYTU) Financial Statements (2026 and earlier)

Company Profile

Business Address 7900 E. UNION AVENUE
DENVER, CO 80237
State of Incorp. DE
Fiscal Year End June 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2025
MRQ
12/31/2024
MRQ
6/30/2024
6/30/2023
6/30/2022
6/30/2021
6/30/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments20,39820,00622,98519,36049,64948,082
Cash and cash equivalent20,39820,00622,98519,36049,64948,082
Restricted cash and investments     252252
Receivables25,40323,61728,93721,71228,1765,176
Inventory, net of allowances, customer advances and progress billings11,08512,63311,99510,84916,3399,999
Inventory11,08512,63311,99510,84916,3399,999
Prepaid expense   8,0477,3759,780 
Other current assets 63,05361,8918686331,0385,742
Other undisclosed current assets(56,886)(56,256)   5,715
Total current assets:63,05361,89172,83259,929105,23474,966
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization   159256329 
Operating lease, right-of-use asset1,1788292,0543,2713,563634
Property, plant and equipment516693   259
Intangible assets, net (including goodwill)49,95852,45358,97070,632151,26649,277
Goodwill     65,80228,090
Intangible assets, net (excluding goodwill)49,95852,45358,97070,63285,46421,187
Deposits noncurrent assets      33
Other noncurrent assets1,5222,22979276646516,587
Other undisclosed noncurrent assets   1,6562,7694,81111,081
Total noncurrent assets:53,17456,20463,63177,694160,43477,871
TOTAL ASSETS:116,227118,095136,463137,623265,668152,836
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities51,07149,01446,79948,95276,48919,849
Taxes payable  175
Employee-related liabilities4,7655,939 
Accounts payable11,69910,440  19,25511,825
Accrued liabilities39,37238,57446,79944,18751,2957,850
Deferred revenue      339
Debt5,8694,2521,6489616,668982
Business combination, contingent consideration, liability     4,055713
Other liabilities7,1088,9627,0905,359 840
Other undisclosed current liabilities  13,47810,03512,2265,583
Total current liabilities:64,04862,22869,01564,442109,43828,307
Noncurrent Liabilities
Long-term debt and lease obligation, including:9,98310,87714,71314,27918011,897
Long-term debt, excluding current maturities9,98310,877   11,171
Finance lease, liability    84180 
Other undisclosed long-term debt and lease obligation   14,71312,105(2,624) 
Liabilities, other than long-term debt11,43117,27413,37812,8108,35717,618
Other liabilities5,0454,5296,97512,8103554,732
Operating lease, liability    2,0902,624725
Business combination, contingent consideration, liability     8,00212,874
Derivative instruments and hedges, liabilities6,38612,7456,403  11
Other undisclosed noncurrent liabilities     10,125 
Total noncurrent liabilities:21,41428,15128,09127,08918,66229,514
Total liabilities:85,46290,37997,10691,531128,10057,821
Equity
Equity, attributable to parent30,76527,71639,35746,092137,56895,015
Common stock1114313
Additional paid in capital348,475347,688343,485334,560315,864215,013
Accumulated deficit(317,711)(319,973)(304,129)(288,472)(178,299)(120,010)
Total equity:30,76527,71639,35746,092137,56895,015
TOTAL LIABILITIES AND EQUITY:116,227118,095136,463137,623265,668152,836

Income Statement (P&L) ($ in thousands)

3/31/2025
TTM
12/31/2024
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
6/30/2020
Revenues68,76481,002107,39996,66965,63227,632
Cost of revenue(22,394)(26,416)(40,767)(44,386)(36,432)(7,553)
Cost of product and service sold(22,394)(26,416)(40,767)(2,186)(7,332) 
Gross profit:46,37054,58666,63252,28329,20020,079
Operating expenses(55,109)(59,840)(83,697)(163,844)(88,070)(48,763)
Other undisclosed operating income      7,553
Operating loss:(8,739)(5,254)(17,065)(111,561)(58,870)(21,131)
Nonoperating income3,138568141,2788407,510
Other nonoperating income (expense)3,138568(4,779)(862)(2,050) 
Interest and debt expense(2,073) (9)(14)(1,569)(316)
Other undisclosed loss from continuing operations before equity method investments, income taxes(4,792)     
Loss from continuing operations before equity method investments, income taxes:(12,466)(4,686)(17,060)(110,297)(59,599)(13,936)
Other undisclosed income (loss) from continuing operations before income taxes7,782(9,390)9141,569 
Income (loss) from continuing operations before income taxes:(4,684)(14,076)(17,051)(110,283)(58,030)(13,936)
Income tax expense (benefit)(1,062)(1,768) 110(259) 
Income (loss) from continuing operations:(5,746)(15,844)(17,051)(110,173)(58,289)(13,936)
Loss before gain (loss) on sale of properties:(110,173)(58,289)(13,936)
Income from discontinued operations504     
Net income (loss):(5,242)(15,844)(17,051)(110,173)(58,289)(13,936)
Other undisclosed net income attributable to parent     316
Net income (loss) available to common stockholders, basic:(5,242)(15,844)(17,051)(110,173)(58,289)(13,621)
Dilutive securities, effect on basic earnings per share(5,896)     
Net loss available to common stockholders, diluted:(11,138)(15,844)(17,051)(110,173)(58,289)(13,621)

Comprehensive Income ($ in thousands)

3/31/2025
TTM
12/31/2024
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
6/30/2020
Net income (loss):(5,242)(15,844)(17,051)(110,173)(58,289)(13,936)
Comprehensive income (loss), net of tax, attributable to parent:(5,242)(15,844)(17,051)(110,173)(58,289)(13,936)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: